However, limitations such as heterogeneous tumor permeability and off-target accumulation in reticuloendothelial system organs like the liver and spleen have prompted the development of active targeting strategies, where surface functionalization with ligands (e.g., antibodies, peptides, or aptamers) enables specific binding to overexpressed receptors such as folate receptor alpha or epidermal growth factor receptor (EGFR), resulting in enhanced cellular internalization via receptor-mediated endocytosis and up to 5–10 times greater intratumoral drug levels [5]. Here, EGFR is linked to neoplasm.